Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials

Rheumatology International

Volumn 36, Issue 5, 2016, Pages 663-672

  Lee, Young Ho ^a   Song, Gwan Gyu ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Duloxetine; Fibromyalgia; Milnacipran; Pregabalin

Indexed keywords

DULOXETINE; MILNACIPRAN; PREGABALIN; ANALGESIC AGENT; CYCLOPROPANE DERIVATIVE;

ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FIBROMYALGIA; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; NETWORK META-ANALYSIS; TREATMENT OUTCOME;

ANALGESICS; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DULOXETINE HYDROCHLORIDE; FIBROMYALGIA; HUMANS; NETWORK META-ANALYSIS; PREGABALIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84961822570     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-016-3468-5     Document Type: Article

References (39)

1. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB, Yunus MB (2010) The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res 62:600–610
2. Rossi A, Di Lollo A, Guzzo M, Giacomelli C, Atzeni F, Bazzichi L, Di Franco M (2015) Fibromyalgia and nutrition: what news. Clin Exp Rheumatol 33:S117–S125
3. Clauw DJ (2015) Fibromyalgia and related conditions. Mayo Clin Proc 90:680–692
4. Theoharides TC, Tsilioni I, Arbetman L, Panagiotidou S, Stewart JM, Gleason RM, Russell IJ (2015) Fibromyalgia syndrome in need of effective treatments. J Pharmacol Exp Ther 355:255–263
5. Calandre EP, Rico-Villademoros F, Slim M (2015) An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother 16:1347–1368
6. Schuessler B (2006) What do we know about duloxetine’s mode of action? Evidence from animals to humans. BJOG Int J Obstet Gynaecol 113:5–9
7. Leo RJ, Brooks VL (2006) Clinical potential of milnacipran, a serotonin and norepinephrine reuptake inhibitor, in pain. Curr Opin Investig Drugs 7:637–642
8. Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ (2004) Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55:320–322
9. Lyseng-Williamson KA, Siddiqui MA (2008) Pregabalin: a review of its use in fibromyalgia. Drugs 68:2205–2223
10. Häuser W, Petzke F, Sommer C (2010) Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. J Pain 11:505–521
11. Lunn MP, Hughes RA, Wiffen PJ (2014) Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev (CDSR) 1:1–126
12. Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ (2015) Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev (CDSR) 10:1–70
13. Tzellos TG, Toulis KA, Goulis DG, Papazisis G, Zampeli VA, Vakfari A, Kouvelas D (2010) Gabapentin and pregabalin in the treatment of fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 35:639–656
14. Lee YH, Bae SC, Choi SJ, Ji JD, Song GG (2011) Associations between vitamin D receptor polymorphisms and susceptibility to rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 38:3643–3651
15. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2007) PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int 27:827–833
16. Lee YH, Choi SJ, Ji JD, Song GG (2012) Candidate gene studies of fibromyalgia: a systematic review and meta-analysis. Rheumatol Int 32:417–426
17. Caldwell DM, Ades A, Higgins J (2005) Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ Br Med J 331:897
18. Lee YH, Bae SC, Song GG (2015) Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Rheumatol Int 35:1965–1974
19. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum Arthritis Care Res 33:160–172
20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12
21. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269
22. Brown S, Hutton B, Clifford T, Coyle D, Grima D, Wells G, Cameron C (2014) A Microsoft-Excel-based tool for running and critically appraising network meta-analyses—an overview and application of NetMetaXL. Syst Rev 3:1–11
23. Salanti G, Ades A, Ioannidis JP (2011) Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 64:163–171
24. Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades A (2013) Evidence synthesis for decision making 4 inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33:641–656
25. Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I (2012) Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods 3:98–110
26. Valkenhoef G, Lu G, Brock B, Hillege H, Ades A, Welton NJ (2012) Automating network meta-analysis. Research synthesis. Methods 3:285–299
27. Arnold LM, Rosen A, Pritchett YL, D’Souza DN, Goldstein DJ, Iyengar S, Wernicke JF (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5–15
28. Russell IJ, Mease PJ, Smith TR, Kajdasz DK, Wohlreich MM, Detke MJ, Walker DJ, Chappell AS, Arnold LM (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136:432–444
29. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y (2008) Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30:1988–2004
30. Branco JC, Zachrisson O, Perrot S, Mainguy Y, Multinational Coordinator Study G (2010) A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 37:851–859
31. Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y (2010) Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum Arthritis Care Res 62:2745–2756
32. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, Young JP Jr, LaMoreaux LK, Martin SA, Sharma U, Pregabalin -105 Study G (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum Arthritis Care Res 52:1264–1273
33. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, Sharma U (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35:502–514
34. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, Martin SA, Barrett JA, Haig G (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9:792–805
35. Pauer L, Winkelmann A, Arsenault P, Jespersen A, Whelan L, Atkinson G, Leon T, Zeiher B, Investigators A (2011) An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia. J Rheumatol 38:2643–2652
36. Catalá-López F, Tobías A, Cameron C, Moher D, Hutton B (2014) Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int 34:1489–1496
37. Choy E, Smith C, Dore C, Scott D (2005) A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 44:1414–1421
38. Ravindran V, Scott D, Choy E (2008) A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. Ann Rheum Dis 67:855–859
39. Nüesch E, Häuser W, Bernardy K, Barth J, Jüni P (2013) Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962